Keiichi Fukuda is a pioneer of the cardiac regeneration field and has been at its cutting edge for the past 20 years. He has made several contributions to the regenerative medicine of the failing heart using iPS cells. He developed a novel method to purify the cardiomyocytes by metabolic selection. He became Chief Professor of the Department of Cardiology at Keio University and published more than 800 top-ranked papers. He established the bio-venture company “Heartseed Inc.” in 2015 and became CEO. He is now examining the clinical trial for transplanting human iPS-derived regenerated cardiomyocytes to patients with congestive heart failure.